Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01956812 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
A Phase 3 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 334
- Enrollment target
NCT01956812 is a Phase 3 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 334 participants.
The verdict
NCT01956812, a Phase 3 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 334 participants
- Enrollment target
Study Summary
The is a double-blind, randomized phase 3 study of 90Y-clivatuzumab tetraxetan with low-dose gemcitabine, versus placebo and low-dose gemcitabine in metastatic pancreatic cancer patients who have progressed on at least 2 prior therapies for metastatic cancer (1 of which was a gemcitabine-containing regimen).
Interventions
- DRUG placebo
- DRUG Gemcitabine
- DRUG IMMU-107
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 334 participants |
| Start Date | 2013-12 |
| Est. Completion | 2016-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01956812
The ClinicalTrials.gov registry entry for NCT01956812 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 334 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01956812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01956812 about?
NCT01956812 is a clinical study titled "Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer". The is a double-blind, randomized phase 3 study of 90Y-clivatuzumab tetraxetan with low-dose gemcitabine, versus placebo and low-dose gemcitabine in metastatic pancreatic cancer patients who have progressed on at least 2 prior therapies for metastatic cancer (1 of which was a gemcitabine-containing ...
What is the current status of trial NCT01956812?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 334 participants. The study started on 2013-12. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01956812?
The interventions under investigation include: placebo (DRUG), Gemcitabine (DRUG), IMMU-107 (DRUG).
Who is sponsoring clinical trial NCT01956812?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.